Liquidia (LQDA) Shares Outstanding (Diluted Average) (2020 - 2026)
Liquidia (LQDA) recorded quarterly Shares Outstanding (Diluted Average) of $101.1 million in Q1 2026, up 17.49% quarter-over-quarter from $86.1 million in Q4 2025, and up 18.71% on a YoY basis from $85.2 million in Q1 2025.
Liquidia (LQDA) Shares Outstanding (Diluted Average) (2020 - 2026) Analysis & Trends
Liquidia's Shares Outstanding (Diluted Average) history runs 7 years deep, the most recent figure standing at $101.1 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 18.71% year-over-year to $101.1 million; the TTM figure through Mar 2026 stood at $101.1 million (up 18.71% YoY), while the FY2025 annual figure was $86.1 million, up 9.34% from the prior year.
- Shares Outstanding (Diluted Average) was $101.1 million for Q1 2026 at Liquidia, up from $86.1 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $101.1 million in Q1 2026 to a low of $52.5 million in Q1 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $73.2 million across 5 years, with a median of $75.4 million in 2024.
- Biggest YoY gain for Shares Outstanding (Diluted Average) was 23.24% in 2023; the steepest drop was 4.2% in 2023.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $61.0 million in 2022, then rose by 6.62% to $65.0 million in 2023, then grew by 21.1% to $78.7 million in 2024, then increased by 9.34% to $86.1 million in 2025, then rose by 17.49% to $101.1 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $101.1 million (Q1 2026), $86.1 million (Q4 2025), and $85.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 1.18 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 422.40 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 47.20 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 103.40 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 506.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | 228.36 Mn |
| 10 | Liquidia | 5.74 Bn | 5.52 Bn | 121.79 Mn | 101.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 101.11 Mn |
| Dec 31, 2025 | 86.06 Mn |
| Sep 30, 2025 | 85.70 Mn |
| Jun 30, 2025 | 85.38 Mn |
| Mar 31, 2025 | 85.17 Mn |
| Dec 31, 2024 | 78.71 Mn |
| Sep 30, 2024 | 76.72 Mn |
| Jun 30, 2024 | 75.91 Mn |
| Mar 31, 2024 | 75.39 Mn |
| Dec 31, 2023 | 64.99 Mn |
| Sep 30, 2023 | 64.77 Mn |
| Jun 30, 2023 | 64.79 Mn |
| Mar 31, 2023 | 64.66 Mn |
| Dec 31, 2022 | 60.96 Mn |
| Sep 30, 2022 | 59.75 Mn |
| Jun 30, 2022 | 62.18 Mn |
| Mar 31, 2022 | 52.47 Mn |
| Dec 31, 2021 | 49.68 Mn |
| Sep 30, 2021 | 48.82 Mn |
| Jun 30, 2021 | 50.85 Mn |